PHARMACEUTICALS

SECOND QUARTER 2024 EARNINGS CONFERENCE CALL

AUGUST 2024



Today's Agenda

Business Update

Terrie Curran, President & Chief Executive Officer

> US Commercial Launch Progress Martin Gilligan, Chief Commercial Officer

Second Quarter 2024 Results Molly Henderson, Chief Financial & Business Officer

Closing Remarks

Terrie Curran, President & Chief Executive Officer

Question & Answer

Terrie Curran, President & Chief Executive Officer Martin Gilligan, Chief Commercial Officer Molly Henderson, Chief Financial & Business Officer Azmi Nabulsi, Chief Operating Officer



Safe harbor

This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, anticipated milestones, anticipated cash runway, expectations of generating stability data necessary to support the proposed shelf life of vonoprazan, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and anticipated products, are forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors include, without limitation: our ability successfully to commercialize approved products containing vonoprazan; our new drug application for non-erosive GERD may not be approved by the FDA; our planned clinical trials of vonoprazan as an as need treatment for non-erosive GERD or for eosinophilic esophagitis may not successfully be initiated or completed: we may not be successful in expanding commercial coverage for our approved products; the inherent risks of clinical development of vonoprazan; our dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; our ability to obtain and maintain intellectual property protection and non-patent regulatory exclusivity for approved products containing vonoprazan, including GAIN Act exclusivity tied to the active molety, vonoprazan; our ability to comply with our license agreement with Takeda; our ability to achieve and maintain adequate levels of coverage and reimbursement for vonoprazan; the availability of additional funds under our revenue interest financing agreement and term loan agreement; the sufficiency of our capital to fund our operations, including that we may not be able to access \$100 million of our term loan which is subject to achievement of specified revenues milestones; and other risks described in our filings with the Securities and Exchange Commission (SEC), including our most recent Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to revise or update this presentation to reflect events or circumstances after the date hereof. All forward-looking statements are gualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

This presentation contains non-GAAP financial measures, which should be considered only a supplement to, and not a substitute for or superior to, GAAP measures. Refer to the Reconciliation of Non-GAAP Financial Measures to GAAP Results table on pages 17 and 18 of this presentation.




Business Update

Terrie Curran, President & Chief Executive Officer



VOQUEZNA label expanded with 3rd indication for largest GERD target market



¹ El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871-880. doi:10.1136/gutjnl-2012-304269 ² Machicado J.D., Greer J.B., Yadav D. (2020) Epidemiology of Gastrointestinal Diseases. In: Pitchumoni C., Dharmarajan T. (eds) Geriatric Gastroenterology. Springer, Cham. https://doi.org/10.1007/978-3-319-90761-1_7-1 ³ Company estimates based on its market research.



Expanded access and growing demand paired with positive patient feedback





"I have experienced **amazing results**. I have suffered for years with GERD and **this has changed my life**."

"This medicine has **helped me immensely**, I have not had any GERD issues since I started taking the samples and have even been **sleeping so much better**." "I have tried every medication out there. VOQUEZNA is the **only medication that has improved my condition**."

> "I have been on a number of PPIs and I recently researched and found VOQUEZNA. It worked well and was really **a game changer**."



¹ Per MMIT formulary lookup tool as of 8/2/2024.
² Unique prescriptions written; IQVIA + BlinkRx as of 7/26/24.
³ IQVIA + BlinkRx as of 7/26/24.
⁴ Actual VOQUEZNA patients. Results not typical.

Planned development focused on furthering vonoprazan's differentiation

Rapid ¹		Potent ¹		Durable ¹	
-	Target indications	Phase 1	Phase 2	Phase 3	Milestones
Non-Erosive GERD	As Needed treatment of heartburn associated with Non-Erosive GERD		PHALCOP a fund		Positive Phase 2 results reported Planning to initiate Phase 3 trial in 2024
Eosinophilic Esophagitis	Treatment of eosinophilic esophagitis (EoE) for adult & pediatric use				Planning to initiate Phase 2 trial in 2024



VOQUEZNA® (vonoprazan) tablets ^{10 mg} 20 mg

RAPID POTENT DURABLE

R



US Commercial Launch Progress

Martin Gilligan, Chief Commercial Officer



Demonstrated great progress in Q2, generating awareness and demand



Previously: 43,000+ (as of 4/26/24)

60,000+

Filled VOQUEZNA Prescriptions²

Previously: 17,500+ (as of 4/26/24)




Previously: 3,800+ (as of 4/19/24)






Continued growth in key metrics leading into the Non-Erosive launch





Widespread commercial coverage achieved with several large payers





ONCE-DAILY PILL PROVEN TO HELP RELIEVE HEARTBURN

CONTRACTOR OF CO



NOW APPROVED FOR NON-EROS/VE



VOQUEZNA® (vonoprazan) tablets ^{10 mg} 20 mg

RAPID POTENT DURABLE

R




Second Quarter 2024 Results

Molly Henderson, Chief Financial & Business Officer




Key financial measures: Net Revenues




Sequential Comparison

Year Over Year Comparison





Key financial measures: Operating Expenses



Key financial measures: Adjusted Net Loss and Cash

Reconciliation of GAAP to Non-GAAP Adjusted Net Loss

(in thousands, except per share amounts)

	<u>Q2 2024</u>	<u>Q1 2024</u>
GAAP net loss	(\$91,446)	(\$82,852)
Stock-based compensation expense	\$6,099	\$5,626
Non-cash interest on revenue interest financing liability	\$11,553	\$11,956
Interest expense related to amortization of debt discount	\$499	\$474
Non-GAAP adjusted net loss	(\$73,295)	(\$64,796)
Non-GAAP net loss per share	(\$1.25)	(\$1.11)

\$276.2M

in cash and cash equivalents as of June 30, 2024

We believe this balance and other anticipated capital¹ will be sufficient to fund operations through the end of 2026



VOQUEZNA® (vonoprazan) tablets ^{10 mg} 20 mg

RAPID POTENT DURABLE

R



Closing Remarks

Terrie Curran, President & Chief Executive Officer



Question & Answer

Terrie Curran, President & Chief Executive Officer Martin Gilligan, Chief Commercial Officer Molly Henderson, Chief Financial & Business Officer Azmi Nabulsi, Chief Operating Officer

